Document Detail


Lack of methemoglobinemia with flutamide.
MedLine Citation:
PMID:  11197580     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To determine whether the nonsteroidal antiandrogenic drug flutamide is a clinically relevant inducer of methemoglobinemia in patients with prostatic cancer. METHODS: Fifty consecutive outpatients with prostatic cancer stage D2 entered the study (age 71.1 +/- 7.3 y). Five patients were lost to follow-up; the remaining 45 patients received the recommended oral dose of flutamide 250 mg three times daily. Total hemoglobin (Hb) and methemoglobin (Met-Hb) concentrations were measured on varying days using an ultraviolet/visible-spectrophotometric method with an intra- and interday variability < 8%. In 12 patients, Met-Hb was analyzed before initiating flutamide therapy and after therapy was begun. RESULTS: On average, 2.6 venous blood samples per patient were analyzed with a mean Met-Hb concentration of 1.9% of total Hb. Mean concentrations of > or = 3% were detected in only six patients (13%). The data from 12 patients evaluated before and after initiating flutamide therapy were without significantly different changes. During the study period, no clinical signs of methemoglobinemia were reported or observed. CONCLUSIONS: This study found no clinically relevant increase of Met-Hb concentrations in elderly patients with prostatic cancer during chronic treatment with flutamide. However, clinicians should be aware of the very rare possibility of flutamide-induced methemoglobinemia.
Authors:
M Schulz; A Schmoldt; F Donn; H Becker
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  35     ISSN:  1060-0280     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2001-01-25     Completed Date:  2001-03-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  21-5     Citation Subset:  IM    
Affiliation:
Center for Drug Information and Pharmacy Practice, ABDA-Federal Union of German Associations of Pharmacists, Eschborn, Germany. M.Schulz@abda.aponet.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antineoplastic Agents, Hormonal / adverse effects,  therapeutic use*
Flutamide / adverse effects,  therapeutic use*
Humans
Male
Methemoglobin / drug effects,  metabolism
Methemoglobinemia / chemically induced*
Middle Aged
Prostatic Neoplasms / blood,  drug therapy*,  pathology
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 13311-84-7/Flutamide; 9008-37-1/Methemoglobin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observatio...
Next Document:  Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.